CN116590175A - Lactobacillus fermentum ELF041 and application thereof - Google Patents
Lactobacillus fermentum ELF041 and application thereof Download PDFInfo
- Publication number
- CN116590175A CN116590175A CN202310382706.8A CN202310382706A CN116590175A CN 116590175 A CN116590175 A CN 116590175A CN 202310382706 A CN202310382706 A CN 202310382706A CN 116590175 A CN116590175 A CN 116590175A
- Authority
- CN
- China
- Prior art keywords
- elf041
- atherosclerosis
- lactobacillus fermentum
- product
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186840 Lactobacillus fermentum Species 0.000 title claims abstract description 46
- 229940012969 lactobacillus fermentum Drugs 0.000 title claims abstract description 46
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 33
- 230000000968 intestinal effect Effects 0.000 claims abstract description 23
- 230000003187 abdominal effect Effects 0.000 claims abstract description 10
- 230000000694 effects Effects 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 235000013305 food Nutrition 0.000 claims description 9
- 238000004321 preservation Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 230000003143 atherosclerotic effect Effects 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 229940127557 pharmaceutical product Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
- 244000046052 Phaseolus vulgaris Species 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 7
- 235000013311 vegetables Nutrition 0.000 abstract description 4
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 230000002792 vascular Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 48
- 230000001580 bacterial effect Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 7
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010024212 E-Selectin Proteins 0.000 description 6
- 102000015689 E-Selectin Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000000702 aorta abdominal Anatomy 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000497 foam cell Anatomy 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 241000606125 Bacteroides Species 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 241000589989 Helicobacter Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000009654 indole test Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 241001464948 Coprococcus Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000605716 Desulfovibrio Species 0.000 description 1
- 102100038591 Endothelial cell-selective adhesion molecule Human genes 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000882622 Homo sapiens Endothelial cell-selective adhesion molecule Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 101000622131 Rattus norvegicus E-selectin Proteins 0.000 description 1
- 101000599859 Rattus norvegicus Intercellular adhesion molecule 1 Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- -1 VCAM-1 Proteins 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000021070 high sugar diet Nutrition 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A lactobacillus fermentum ELF041 and application thereof belong to the technical field of microorganisms. In order to prevent and/or treat atherosclerosis, the invention provides lactobacillus fermentum (Lactispicellum) ELF041 separated from fermented salted vegetable, and by establishing a rat atherosclerosis model, the strain ELF041 is found to have a certain regulation and control effect on the body mass of an atherosclerosis rat, can improve the integrity of the abdominal aortic vascular wall of the atherosclerosis patient, reduce the adhesion factor level in the plasma of the atherosclerosis patient and regulate the intestinal flora of the atherosclerosis patient, thereby proving that the strain ELF041 has good prevention and treatment effects on atherosclerosis. Therefore, the lactobacillus fermentum ELF041 provided by the invention has wide application value.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus fermentum ELF041 and application thereof.
Background
Atherosclerosis (As) is a common disease that endangers human health, and the resulting cardiovascular and cerebrovascular diseases have become the leading cause of death in China and even worldwide. The main pathologies of atherosclerosis are represented by lipid deposition of the intima of the artery, inflammatory cell infiltration, smooth muscle cell and matrix proliferation, intimal thickening, lumen stenosis, thrombosis, etc. It is a complex pathological process involving multiple factors and regulated by multiple abnormal genes. In recent years, atherosclerosis is considered to be a protective inflammatory reaction to local injury of blood vessels, and when the injury lasts for a certain time, the intima of the blood vessels is fibrosed, and plaque is finally formed. The long-term high-fat and high-sugar diet can also cause structural disturbance of intestinal flora, enrichment of harmful microorganisms in intestinal tracts, induction of increase of adhesion factors (such AS ICAM-1, VCAM-1 and E-Selectin) in blood vessels of organisms, and promotion of AS formation.
Meanwhile, in the research of cardiovascular disease risk factors, intestinal flora is getting more and more attention. In recent years, research shows that the intestinal flora structure of AS patients and healthy people has obvious difference, and the intestinal flora component change and the occurrence and development of dysfunctional AS play an important role, so the AS has become a new target for preventing and treating AS. The intestinal flora consists of trillion symbiotic microorganisms, maintains survival and metabolism by nutritional ingredients in human bodies, reacts with the human bodies to external environment factors together, and performs metabolism and immune activities to maintain the health of the human bodies. Therefore, the Chinese medicinal composition has the important significance of regulating intestinal flora disturbance of patients with atherosclerosis, improving inflammatory response of organisms and preventing and treating AS.
Lactobacillus fermentum (lactobacillus) is widely distributed in the gastrointestinal tract as a potential probiotic, and is the normal flora of the intestinal tract, oral cavity and vagina. In recent years, the functional characteristics of lactobacillus fermentum are continuously mined, such as acid resistance, bile salt resistance, cholesterol degradation, oxidation resistance, bacteriostasis and the like, and the lactobacillus fermentum can also regulate the balance of host microorganism flora, can reach intestinal tracts through oral administration, well adsorb epithelial cells in small intestines, generate surface active ingredients, prevent harmful bacteria from adhering to the intestinal tracts, thereby improving the system environment in a host body and promoting the health of the host. Along with the continuous discovery of the probiotic characteristics of lactobacillus fermentum, the lactobacillus fermentum has wide application in the fields of food fermentation, medical care and the like. Therefore, the lactobacillus fermentum has wide development prospect in the aspect of preventing and treating cardiovascular diseases.
Disclosure of Invention
In order to prevent and/or treat atherosclerosis, the invention provides lactobacillus fermentum (Lactiplantibacillus fermertum) ELF041, which is preserved in China center for type culture collection, and the preservation number is CCTCC NO: m20221240, the preservation date is 2022, 8 and 4, and the preservation unit address is the university of Wuhan, mitsui, jiujingjingku, wuhan, hubei province.
The invention also provides application of the lactobacillus fermentum E/LF041 in preparation of products for preventing and/or treating atherosclerosis.
Further defined, the amount of Lactobacillus fermentum ELF041 in the product is 1X 10 9 CFU/mL or 1X 10 9 CFU/g。
Further defined, the product has at least one of the following effects:
(1) Improving the quality of the body of the patient suffering from atherosclerosis;
(2) Improving the integrity of the abdominal aortic vessel wall of the atherosclerosis patient;
(3) Reducing the level of adhesion factor in the plasma of an atherosclerotic patient;
(4) Regulating intestinal flora of patients with atherosclerosis.
Further defined, the product includes, but is not limited to, a food, a nutraceutical, or a pharmaceutical product.
Further defined, the pharmaceutical product contains a pharmaceutical carrier and/or pharmaceutical excipients.
Further defined, the drug carrier includes, but is not limited to, microcapsules, microspheres, nanoparticles, and liposomes.
Further defined, the dosage forms of the pharmaceutical product include, but are not limited to, powders, granules, capsules, tablets, pills, and oral liquids.
Further defined, the food products include, but are not limited to, dairy products, soy products, and fruit and vegetable products.
The invention also provides a product for preventing and/or treating atherosclerosis by taking the lactobacillus fermentum ELF041 as an active ingredient, which is characterized by comprising medicines, health products or foods.
Further defined, the product has at least one of the following effects:
(1) Improving the quality of the body of the patient suffering from atherosclerosis;
(2) Improving the integrity of the abdominal aortic vessel wall of the atherosclerosis patient;
(3) Reducing the level of adhesion factor in the plasma of an atherosclerotic patient;
(4) Regulating intestinal flora of patients with atherosclerosis.
The invention has the beneficial effects that:
according to the invention, lactobacillus fermentum (ELF 041) is screened, and a rat atherosclerosis model is established, so that the strain ELF041 has a certain regulation and control effect on the quality of an atherosclerosis rat, can improve the integrity of the abdominal aortic vascular wall of an atherosclerosis patient, reduce the adhesion factor level in the plasma of the atherosclerosis patient and regulate the intestinal flora of the atherosclerosis patient, thereby proving that the strain ELF041 has good prevention and treatment effects on atherosclerosis. Therefore, the lactobacillus fermentum ELF041 provided by the invention has wide application value.
Drawings
FIG. 1 is a graph showing the effect of Lactobacillus fermentum ELF041 on the histopathological characteristics of the rat abdominal aorta; wherein, A in FIG. 1 is the abdominal aortic tissue pathological section (200X) of the rats in the blank group, B in FIG. 1 is the abdominal aortic tissue pathological section (200X) of the rats in the model group, and C in FIG. 1 is the abdominal aortic tissue pathological section (200X) of the rats in the ELF041 group; in FIG. 1, solid arrows indicate the amount of calcium salt deposited, and broken arrows indicate foam cells;
FIG. 2 is a graph showing the results of the detection of the adhesion factor index of each group of rats; wherein # in fig. 2 indicates that the difference is extremely significant (P < 0.01) compared to the blank group; * Represents that the differences were very significant compared to the model group (P < 0.01);
FIG. 3 is a graph showing changes in intestinal flora in rats of each group; wherein C in the graph 3 is a blank group, M in the graph 3 is a model group, and Z in the graph 3 is an ELF041 group.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be further described in detail with reference to the following detailed description and the accompanying drawings. The experimental methods used in the examples below were conventional, and the materials, reagents, methods and apparatus used, unless otherwise indicated, were all conventional in the art and commercially available to those skilled in the art.
The composition of the solid MRS medium used in the following examples was: 10g/L of peptone, 10g/L of beef extract, 5g/L of yeast extract powder, 5g/L of sodium acetate, 5g/L of sodium citrate, 2g/L of dipotassium hydrogen phosphate, 0.2g/L of magnesium sulfate, 0.05g/L of manganese sulfate, 80g/L of tween, 20g/L of glucose, 15g/L of agar and the balance of water; ph=7.0 unless otherwise specified. Liquid MRS medium differs from solid MRS medium only in that no agar is added to the liquid MRS medium.
SPF-grade healthy male SD rats (8 weeks old) weighing 180 g-210 g, purchased from Liaoning long Biotechnology Co., ltd. The animals are fed adaptively for one week, the temperature of the animal house is 21+/-2 ℃, the relative humidity is (40+/-10)%, and feeding and drinking are carried out freely.
Basal feed: yisi laboratory animal technology, inc. of Changchun City.
High fat feed (% stands for g/100 g): sucrose 20%, lard 10%, cholesterol 2.5%, sodium cholate 0.5%, yolk powder 5% and basic feed 62%.
Rat intercellular adhesion molecule 1 (ICAM-1) enzyme-linked immunosorbent assay kit: jiangsu enzyme-labeled Biotech Co.
Rat vascular endothelial cell adhesion molecule 1 (VCAM-1) enzyme-linked immunosorbent assay kit: jiangsu enzyme-labeled Biotech Co.
Rat E Selectin (E-Selectin) enzyme-linked immunosorbent assay kit: jiangsu enzyme-labeled Biotech Co.
The quantitative tests in the following examples were all set up in triplicate and the results averaged.
Example 1: isolation, identification and preservation of Lactobacillus fermentum ELF041
(1) Isolation of Lactobacillus fermentum ELF041
Sample material selection: salted vegetable of traditional fermented food.
And 9 months in 2020, a fresh salted vegetable sample collected from Changchun, jilin province is placed in a transportation medium, quickly placed in an ice box and sent to a laboratory for strain separation. The salted vegetable sample is treated in water bath at 80 ℃ for 10 minutes, then is ground, diluted in a gradient way and uniformly coated on an MRS solid culture medium plate, is cultured for 24 hours at 37 ℃, single bacterial colony is selected and inoculated on the MRS solid culture medium plate for continuous culture, and is repeatedly streaked, cultured and purified by the MRS solid culture medium plate to obtain a plurality of pure bacterial colonies. The pure cultured strain is inoculated into a liquid MRS culture medium for culture, and then 60 percent of glycerol is added for preservation in a refrigerator at the temperature of minus 80 ℃. Of which 1 strain was numbered ELF041.
(2) Identification of Lactobacillus fermentum ELF041
Physiological and biochemical identification of strain ELF 041: including gram stain tests, catalase tests, benzidine tests, indole tests, acetomethyl methanol tests, optimum growth temperature tests, optimum pH tests, salt tolerance tests, growth state observations and the like. The results show that the strain ELF041 shows gram-positive staining, negative catalase test, negative benzidine test, negative indole test and positive acetomethyl methanol test; the optimal growth temperature is 37 ℃; the pH is suitably 5.0-7.0; is tolerant to 6.5% NaCl solution; ELF041 shows uniform turbid growth in MRS liquid culture medium, and long-standing thalli shows white precipitation.
Molecular biological identification of Strain ELF 041: bacterial strain ELF041 with good growth vigor is inoculated in MRS liquid culture medium, and is subjected to stationary culture in an incubator at 37 ℃ for 16-18 hours to obtain bacterial liquid, mycelia are collected after centrifugation and are put in an EP tube, and the bacterial strain ELF041 genome DNA is extracted by using a bacterial genome DNA extraction kit after being washed with sterile water for 2 times. And (3) taking the extracted DNA product as a template, carrying out PCR amplification by adopting an upstream primer with a nucleotide sequence shown as SEQ ID NO.1 (5'-AGAGTTTGATCCTGGCTCAG-3') and a downstream primer with a nucleotide sequence shown as SEQ ID NO.2 (5'-AGAAAGGAGGTGATCCAGC-3'), and sequencing the amplified product to obtain the 16S rDNA sequence of the strain ELF041. As a result of homology alignment analysis of the 16s rDNA sequence in GenBank library by BLAST program, it was found that the homology with Lactobacillusfermentum GERU1 (GenBank: MK 639007.1) was 99.00%. The 16s rDNA sequence of strain ELF041 is shown in SEQ ID NO.3: AATGCAGTCGAACGCGTTGGCCCAATTGATTGATGGTGCTTGCACCTGATTGATTTTGGTCGCCAACGAGTGGCGGACGGGTGAGTAACACGTAGGTAACCTGCCCAGAAGCGGGGGACAACATTTGGAAACAGATGCTAATACCGCATAACAGCGTTGTTCGCATGAACAACGCTTAAAAGATGGCTTCTCGCTATCACTTCTGGATGGACCTGCGGTGCATTAGCTTGTTGGTGGGGTAACGGCCTACCAAGGCGATGATGCATAGCCGAGTTGAGAGACTGATCGGCCACAATGGGACTGAGACACGGCCCATACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGGCGCAAGCCTGATGGAGCAACACCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAGCTCTGTTGTTAAAGAAGAACACGTATGAGAGTAACTGTTCATACGTTGACGGTATTTAACCAGAAAGTCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGAGAGTGCAGGCGGTTTTCTAAGTCTGATGTGAAAGCCTTCGGCTTAACCGGAGAAGTGCATCGGAAACTGGATAACTTGAGTGCAGAAGAGGGTAGTGGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTACCTGGTCTGCAACTGACGCTGAGACTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAGTGCTAGTGTTGGAGGGTTTCCGCCCTTCAGTGCCGGAGCTAACGCATTAAGCACTCCGCCTGGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAGACTTACCAGTCTTGACATCTGCGCATCTAGAGATAGGCGTTTCTCGGACGCATGA
Based on the above identification, strain ELF041 was identified as Lactobacillus fermentum (Lactiplantibacillus fermertum).
(3) Preservation of Lactobacillus fermentum ELF041
The lactobacillus fermentum ELF041 screened by the invention is preserved in China Center for Type Culture Collection (CCTCC) NO: m20221240, the preservation date is 2022, 8 and 4, and the preservation unit address is the university of Wuhan, mitsui, jiujingjingku, wuhan, hubei province.
Example 2: application of lactobacillus fermentum ELF041 in preventing and/or treating atherosclerosis
(1) Preparation of lactobacillus fermentum ELF041 bacterial suspension:
inoculating lactobacillus fermentum ELF041 into liquid MRS culture medium, standing in 37 deg.C incubator for 16-18 h, centrifuging at 4 deg.C for 10min, discarding supernatant to obtain bacterial precipitate, preparing bacterial suspension from bacterial mud with sterile physiological saline, and obtaining bacterial suspension according to OD 600 Absorbance and plate count results, the concentration of the bacterial suspension was adjusted to 1×10 9 CFU/mL。
(2) Feeding and grouping of experimental animals:
21 SPF-grade healthy male SD rats were subjected to adaptive feeding for one week, and feeding and drinking were freely performed by the rats. After one week, rats were randomly divided into 3 groups (blank, model and ELF041 groups) of 7 animals each. The model group and the treatment group were intraperitoneally injected with vitamin D3 injection at a total dose of 700000U/kg on days 3, 5, and 7 of the adaptive feeding to establish an SD rat atherosclerosis model, and the model construction was confirmed to be successful by verification. The blank group was intraperitoneally injected with an equal amount of physiological saline, and body weight was recorded every three days.
The treatment methods of each group are as follows:
blank group: and feeding with basic feed and drinking water freely. Normal saline (2 mL for a single administration) was infused once daily for a total of 7 weeks, and the animals were sacrificed the next day after the end of the last experiment without water withdrawal from food.
Model group: feeding with high fat fodder, and drinking water. Normal saline (2 mL for a single administration) was infused once daily for a total of 7 weeks, and the animals were sacrificed the next day after the end of the last experiment without water withdrawal from food.
ELF041 group: feeding with high fat fodder, and drinking water. The lactobacillus fermentum ELF041 bacterial suspension (1×10) obtained in step (1) is filled once per day 9 CFU/mL), the administration amount was 2mL, and the total treatment was 7 weeks, last timeAfter the intervention treatment is finished, the test animals are sacrificed the next day after fasting without water control.
(3) Rat related physiological index detection:
1. rat body mass detection:
the quality of the three groups of rats after 7 weeks of group feeding was examined, and as a result, it was found that the initial body weight of each group of rats was between 180 and 210g, and there was no significant difference. Since vitamin D3 causes calcification and lesions of rat arteries, which causes inflammatory reaction of rat organism, the weight of rats is slowly increased, and after 7 weeks of group feeding, the weight of rats in model group is increased by 152-168 g, and the average weight is increased by 157.50g; whereas the weight of the rats in the blank group increased by 217-259 g, the average increase was 232.50g, and the difference was significant (P < 0.05) compared with the model group; the ELF041 group of rats had a weight gain of 180-213 g, an average gain of 199.00g (see Table 1), and a marked difference (P < 0.01) compared to the model group. The body mass average positive weight gain of the rats in the ELF041 group ranged between the model group and the blank group, which suggests that Lactobacillus fermentum ELF041 was able to increase the body mass of the atherosclerotic rats.
Table 1 weight and weight change in rats of each group
Note that: group-to-group comparison: # compared to the blank, the difference was significant (P < 0.05); * Compared with the model, the difference is significant (P < 0.05)
2. Rat abdominal aorta histopathological section observation:
the pathological sections of abdominal aorta tissue were observed in three groups of rats 7 weeks after group feeding, and the results are shown in fig. 1. The solid arrows in FIG. 1 indicate the amount of calcium salt deposited, and the dashed arrows indicate foam cells. As shown in fig. 1, the model rats had a disturbed abdominal aortic layer structure, loose endometrial and intimal cell arrangement, a large number of foam cells, and reduced calcium salt deposition compared to the blank rats. In contrast, the pathological section of abdominal aorta tissue of the ELF041 group of rats showed a decrease in foam cell number, an increase in calcium salt deposition, and less structural disorder. It can be seen that lactobacillus fermentum is able to improve the integrity of the abdominal aortic vessel wall of the atherosclerotic rat.
3. Rat adhesion factor index detection:
after 6 weeks of group feeding, rats of each group were injected with sodium pentobarbital anesthesia, incubated at 37℃for 60min after heart blood collection, centrifuged at 3000r/min for 15min, and supernatants were collected and sub-packed in EP tubes and stored in a refrigerator at-80 ℃. ICAM-1, VCAM-1, E-Selectin content in serum was determined with reference to kit instructions.
The results of the serum adhesion factor ICAM-1 content detection are shown as A in FIG. 2, and from the serum adhesion factor ICAM-1 content, the increase of the ICAM-1 level of the rats in the model group is extremely remarkable (P < 0.01) compared with that in the blank group; compared to the model group, rats with ICAM-1 index decreased with the dry prognosis of lactobacillus fermentum ELF041, the difference was very significant (P < 0.01).
The measurement result of the content of the serum adhesion factor VCAM-1 is shown as B in FIG. 2, and from the content of the serum adhesion factor VCAM-1, the increase of the level of the VCAM-1 of rats in the model group is extremely remarkable (P < 0.01) compared with that of the blank group; compared to the model group, rats with VCAM-1 index decreased with the dry prognosis of lactobacillus fermentum ELF041, the differences were very significant (P < 0.01).
The detection result of the content of the serum adhesion factor E-Selectin is shown as C in figure 2, and the increase of the level of the serum adhesion factor E-Selectin in the model group rats is extremely remarkable (P < 0.01) compared with the blank group; compared with the model group, the E-Selectin index of rats was decreased with the dry prognosis of Lactobacillus fermentum ELF041, and the difference was very significant (P < 0.01).
From the above results, it can be seen that lactobacillus fermentum ELF041 has the effect of reducing the adhesion factor level in the plasma of atherosclerotic patients.
4. Detection of intestinal flora of rats:
after the end of the experiment, the cecum of the rats (after 7 weeks of group feeding) was taken, the horizontal abundance of the intestinal flora gate of each group of rats was analyzed, and the abundance of the dominant flora gate was statistically compared, as shown in table 2, and the results found: the dominant mycota of the three groups is Firmicutes, bacteroidetes; model group firmates and bacterioides abundances were reduced compared to the blank group; the ELF041 group had significantly increased Firmiute and Bactroides abundance compared to the model group. Firmicum and Bactoides are dominant beneficial bacteria in the human gut, and thus Lactobacillus fermentum ELF041 can effectively regulate the intestinal flora at the portal level.
Table 2 results of species relative abundance analysis at levels of the intestinal flora gate for each group of rats
The levels of intestinal flora of each group of rats were analyzed and the analysis results are shown in table 3. The microbial abundance in the experimental rat intestinal flora was changed following the administration of lactobacillus fermentum ELF041 dry prognosis. In the model group, the abundance of harmful microorganisms such as Vibrio (Desulfovibrio) and Helicobacter (Helicobacter) is increased as compared with that in the blank group; compared with the model group, the ELF041 group has increased abundance of beneficial microorganisms such as Bacteroides, and the like, which shows that the growth of beneficial intestinal bacteria is promoted, the growth of harmful bacteria is inhibited and the effect of regulating the balance of intestinal flora is achieved through the lactobacillus curvatus ELF041.
TABLE 3 analysis of relative abundance of species at the level of intestinal flora in groups of rats
AS shown in fig. 3, the abundance at 20 different genus levels shows the difference between the dry prognosis of lactobacillus fermentum ELF041 administration and the intestinal flora of AS mice. The model group obviously inhibits the relative abundance of harmful intestinal flora such as Bacteroides (Bacteroides), clostridium (Clostridium), enterococcus faecalis (Coprococcus) and the like, and the abundance of the flora is obviously up-regulated after the dry condition of the administration of the lactobacillus fermentum ELF041.
While the invention has been described with reference to the preferred embodiments, it is not limited thereto, and various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (10)
1. Lactobacillus fermentum (lactobacillus fermentum) ELF041, wherein the lactobacillus fermentum ELF041 has a preservation number of cctcrno: m20221240.
2. Use of lactobacillus fermentum ELF041 according to claim 1 for the preparation of a product for the prevention and/or treatment of atherosclerosis.
3. Use according to claim 2, characterized in that the amount of lactobacillus fermentum ELF041 in the product is 1 x 10 9 CFU/mL or 1X 10 9 CFU/g。
4. The use according to claim 2, wherein the product has at least one of the following effects:
(1) Improving the quality of the body of the patient suffering from atherosclerosis;
(2) Improving the integrity of the abdominal aortic vessel wall of the atherosclerosis patient;
(3) Reducing the level of adhesion factor in the plasma of an atherosclerotic patient;
(4) Regulating intestinal flora of patients with atherosclerosis.
5. The use according to claim 2, wherein the product comprises a food, a nutraceutical or a pharmaceutical product.
6. The use according to claim 5, wherein the food product comprises dairy products, bean products, fruit and vegetable products.
7. The use according to claim 5, wherein the pharmaceutical dosage forms include powders, granules, capsules, tablets, pills and oral liquids.
8. The use according to claim 5, wherein the medicament comprises a pharmaceutical carrier and/or pharmaceutical excipients.
9. The use according to claim 8, wherein the pharmaceutical carrier comprises microcapsules, microspheres, nanoparticles and liposomes.
10. A product for preventing and/or treating atherosclerosis comprising the lactobacillus fermentum ELF041 as an active ingredient according to claim 1, characterized in that the product comprises a pharmaceutical product, a health product or a food product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310382706.8A CN116590175A (en) | 2023-04-12 | 2023-04-12 | Lactobacillus fermentum ELF041 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310382706.8A CN116590175A (en) | 2023-04-12 | 2023-04-12 | Lactobacillus fermentum ELF041 and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116590175A true CN116590175A (en) | 2023-08-15 |
Family
ID=87598012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310382706.8A Pending CN116590175A (en) | 2023-04-12 | 2023-04-12 | Lactobacillus fermentum ELF041 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116590175A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003002131A1 (en) * | 2001-06-29 | 2003-01-09 | University Of Tartu | Strain of micro-organism lactobacillus fermentum me-3 as novel anti-microbial and antioxidative probiotic |
| US20060067921A1 (en) * | 2002-09-06 | 2006-03-30 | Vri Biomedical Ltd | Probiotic bacterium: lactobacillus fermentum |
| US20210023149A1 (en) * | 2019-07-24 | 2021-01-28 | Syngen Biotech. Co., Ltd. | Lactobacillus fermentum strain v3 and its efficacies of intestinal microflora regulation, anti-inflammation and cancer prevention |
| US20210115392A1 (en) * | 2018-03-26 | 2021-04-22 | Genome And Company | Novel Lactobacillus Fermentum LM1016 Strain, And Composition For Preventing Or Treating Cardiovascular Diseases |
| KR102397589B1 (en) * | 2020-11-11 | 2022-05-12 | 고려대학교 산학협력단 | Novel Lactobacillus fermentum MSK 408 strain and composition for preventing or treating of epilepsy comprising Lactobacillus fermentum MSK 408 |
| CN114732834A (en) * | 2022-03-25 | 2022-07-12 | 善恩康生物科技（苏州）有限公司 | Application of lactobacillus fermentum in preparation of product for preventing and/or treating thrombus |
-
2023
- 2023-04-12 CN CN202310382706.8A patent/CN116590175A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003002131A1 (en) * | 2001-06-29 | 2003-01-09 | University Of Tartu | Strain of micro-organism lactobacillus fermentum me-3 as novel anti-microbial and antioxidative probiotic |
| US20060067921A1 (en) * | 2002-09-06 | 2006-03-30 | Vri Biomedical Ltd | Probiotic bacterium: lactobacillus fermentum |
| US20210115392A1 (en) * | 2018-03-26 | 2021-04-22 | Genome And Company | Novel Lactobacillus Fermentum LM1016 Strain, And Composition For Preventing Or Treating Cardiovascular Diseases |
| US20210023149A1 (en) * | 2019-07-24 | 2021-01-28 | Syngen Biotech. Co., Ltd. | Lactobacillus fermentum strain v3 and its efficacies of intestinal microflora regulation, anti-inflammation and cancer prevention |
| KR102397589B1 (en) * | 2020-11-11 | 2022-05-12 | 고려대학교 산학협력단 | Novel Lactobacillus fermentum MSK 408 strain and composition for preventing or treating of epilepsy comprising Lactobacillus fermentum MSK 408 |
| CN114732834A (en) * | 2022-03-25 | 2022-07-12 | 善恩康生物科技（苏州）有限公司 | Application of lactobacillus fermentum in preparation of product for preventing and/or treating thrombus |
Non-Patent Citations (3)
| Title |
|---|
| KIM M 等: "Towards a taxonomic coherence between average nucleotide identity and 16S rRNA gene sequence similarity for species demarcation of prokaryotes", 《INT J SYST EVOLMICROBIOL》, vol. 64, pages 346 - 351, XP055877627, DOI: 10.1099/ijs.0.059774-0 * |
| OH NS 等: "Short communication: Hypolipidemic and antiinflammatory effects of fermented Maillard reaction products by Lactobacillus fermentum H9 in an animal model", 《J DAIRY SCI》, vol. 99, no. 12, pages 9415 - 9423 * |
| 黄玉军 等: "人源性发酵乳杆菌f5降解大鼠胆固醇的研究", 《食品与机械》, vol. 29, no. 6, pages 5 - 9 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113444668B (en) | Bacillus coagulans with blood sugar reducing effect and application thereof | |
| CN116555076B (en) | Bifidobacterium longum subspecies longum MY1 and application thereof in preparation of food and medicine for relaxing bowels and protecting intestines | |
| CN117384788B (en) | Saliva combined lactobacillus SM4 and application thereof in preparation of whitening and cholesterol lowering foods and medicines | |
| CN114854638A (en) | Lactobacillus paracasei for relieving colitis by efficiently expressing adenosine deaminase | |
| CN115820498A (en) | Lactobacillus plantarum YJ2406 and application thereof | |
| CN117721033A (en) | Lactobacillus mucilaginosus KS6 and application thereof in preparation of anti-inflammatory and sleep-aiding foods and medicines | |
| CN117327632A (en) | Bifidobacterium animalis and application thereof | |
| CN113151070B (en) | Lactobacillus fermentum capable of improving relative abundance of Guttiferae in intestinal tract | |
| CN117946939A (en) | Lactobacillus plantarum SM2 and application thereof in preparation of cholesterol-lowering and sleep-aiding foods and medicines | |
| CN113797232A (en) | Composition with function of relieving insulin resistance and application thereof | |
| CN117946940A (en) | Lactobacillus plantarum SM1 and application thereof in preparing food and medicine for regulating intestines and stomach and losing weight | |
| CN113337427A (en) | Lactobacillus plantarum HNU082, composition and application thereof | |
| CN115992059B (en) | Lactobacillus johnsonii for producing feruloyl esterase and application thereof in relieving ulcerative colitis | |
| CN114533768B (en) | Application of lactobacillus probiotics CGMCC No.1.13855 in preparing medicament for treating diabetes | |
| CN116555075A (en) | Lactobacillus plantarum JF1 and application thereof in preparation of anti-aging food and drug | |
| CN116590175A (en) | Lactobacillus fermentum ELF041 and application thereof | |
| CN111603489A (en) | Microbial inoculum for improving constipation and preparation method thereof | |
| CN116410898B (en) | Frozen Wittman's bacteria ELF131 and application thereof | |
| CN117363524B (en) | Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines | |
| CN117946949B (en) | Acremonium muciniphilum and application thereof | |
| CN114404459B (en) | Application of lactobacillus reuteri CCFM1135 in reducing plasma trimethylamine oxide | |
| CN118389372B (en) | Lactobacillus plantarum with functions of losing weight and improving diarrhea | |
| CN117965391B (en) | Acremonium muciniphilum Amuci-1 and application thereof | |
| CN118685300A (en) | Bifidobacterium longum subspecies longum and application thereof in preventing, relieving, regulating or treating lipid metabolism related diseases | |
| CN116656526A (en) | Lactobacillus plantarum JF4 and application thereof in preparation of blood sugar and cholesterol reducing foods and medicines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |